CytoDel is a biopharmaceutical company that uses the tools of 21st century molecular biology to produce recombinant derivatives of botulinum neurotoxin (BoNT) customized to specific applications
The technology allows CytoDel to manipulate the BoNT molecule, for next generation BoNT products and into a drug delivery vehicle that can deliver therapeutic molecules to the inside of neurons
Our lead program utilizes intraneuronal delivery for Biodefense, and additionally, CytoDel is developing programs for the treatment of nervous system disorders and chronic pain. A second program is a Biobetter BoNT offering an improved safety margin and outcomes for the treatment of large muscles and muscle groups.